Combination therapy for multiple sclerosis

International MS Journal

Volumn 11, Issue 1, 2004, Pages 10-21

  Gonsette, R E ^a  

^a National Center for MS   (Belgium)

Author keywords

Combination therapy; Excitotoxicity; Fixed dose regimen; Immune mediated inflammatory cascade; Oxidative toxicity; Sequential combination regimen

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; DACLIZUMAB; FLUOCORTOLONE; FLUOXETINE; GLATIRAMER; IBUPROFEN; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INOSINE; METACYCLINE; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MIZORIBINE; MOCLOBEMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; PARACETAMOL; PENICILLAMINE; PENTOXIFYLLINE; PREDNISONE; RETINOIC ACID; SALBUTAMOL; SELEGILINE; TACROLIMUS; UNINDEXED DRUG;

CLINICAL RESEARCH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG APPROVAL; DRUG DOSE REGIMEN; DRUG EFFICACY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; RELAPSE; REVIEW; SIDE EFFECT; STATISTICAL ANALYSIS;

CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HUMANS; MULTIPLE SCLEROSIS;

EID: 3042787735     PISSN: 13528963     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Lublin FD, Reingold SC. Combination therapy for treatment of multiple sclerosis. Ann Neurol 1998; 44: 7-10.
2. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707-718.
3. Trapp BD, Ransohoff RM, Fisher E, Rudick RA. Neurodegeneration in multiple sclerosis: relationship to neurological disability. Neuroscientist 1999; 5: 48-57.
4. Giuliano F, Goodyer CG, Antel JP, Yong VW. Vulnerability of human neurons to T-cell-mediated cytotoxicity. J Immunol 2003; 171: 368-379.
5. Werner P, Pitt D. Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 2001; 50: 169-181.
6. Milo R, Panitch H. Additive effects of copolymer-1 and interferon beta-1b on the immune response to myelin basic protein. J Neuroimmunol 1995; 61: 185-193.
7. Brod SA, Lindsey JW, Wolinsky JS. Combination therapy with glatiramer acetate (copolymer-1) and a type I interferon (IFN-alpha) does not improve experimental autoimmune encephalomyelitis. Ann Neurol 2000; 47: 127-131.
8. Ying C, Zang Q, Hong J, Robinson RR, Li S, Rivera VM et al. Immune regulatory properties and interactions of copolymer-1 and beta-interferon 1a in multiple sclerosis. AAN 55th Annual Meeting. Neurology 2003; 60 (Suppl 1): A394.
9. Dhib-Jalbut S, Chen M, Henschel K, Ford D, Costello K, Panitch H. Effect of combined IFNβ-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis. Mult Scler 2002; 8: 485-491.
10. Lublin F, Baier M, Cutter G, Bever C, Elfont R, Khan O et al. Results of the extension of a trial to assess longer term safety of combining interferon beta-1a and glatiramer acetate. AAN 54th Annual Meeting. Neurology 2002; 58 (Suppl 3): A85.
11. Le Page E, Coustans M, Taurin G, Chaperon J, Edan G. Induction treatment with the monthly combination mitoxantrone-methylprednisolone for six months followed by a maintenance therapy in worsening relapsing-remitting MS: The clinical benefits last at least four years. AAN 54th Annual Meeting. Neurology 2002; 58 (Suppl 3): A187.
12. Edan G and the Mitoxantrone-Interferon-β-1b European Multicentre Trial Group. The role of intensive immunosuppresion in multiple sclerosis: prospects of combinations. In: Multiple Sclerosis: Tissue Destruction and Repair (Kappos L, Kesselring J, Radü EW, Johnson K, eds). London: Martin Dunitz Ltd, 2001; pp285-290.
13. Jeffery D, Zhu J, Chapuri N, Tan J. The effect of combination therapy with interferon beta-1b and mitoxantrone on enhancing lesion frequency and on the proportion enhancing lesions evolving into T1 'black holes'. ECTRIMS 19th Congress. Mult Scler 2003; 9 (Suppl 1): S70.
14. Moreau T, Blanc S, Riche G, Nony P, Confavreux C. A pilot safety and tolerability study of interferon beta 1a in combination with azathioprine in multiple sclerosis. AAN 53rd Annual Meeting. Neurology 2001; 56 (Suppl 3): A353.
15. Fernandez O, Guerrero M, Mayorga C, Munoz L, Lean A, Luque G et al. Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study. J Neurol 2002; 249: 1058-1062.
16. Horakova D, Havrdova E, Krasensky J, Jinochova M, Dolezal O, Meluzinova E et al. Interferon beta-1a in combination with azathioprine and low-dose steroids for relapsing-remitting multiple sclerosis - preliminary clinical and MRI data from a 2-year double-blind, randomised, placebo-controlled study. ECTRIMS 19th Congress. Mult Scler 2003; 9 (Suppl 1): S144.
17. Markovic-Plese S, Bielekova B, Kadom N, Leist TP, Martin R, Frank JA et al. Longitudinal MRI study: the effects of azathioprine in MS patients refractory to interferon beta-1b. Neurology 2003; 60: 1849-1851.
18. Greenstein J, Rae-Grant AD, Eckert N. A safety study of combination treatment with interferon beta-1a (Avonex) and azathioprine in breakthrough multiple sclerosis. ECTRIMS 19th Congress. Mult Scler 2003; 9 (Suppl 1): S140.
19. Aldinucci A, Biagioli T, Mozzanti B, Ballerini C, Vergelli M, Massacesi L. Interactions of IFNb and azathioprine association in vitro and in multiple sclerosis. ECTRIMS 19th Congress. Mult Scler 2003; 9 (Suppl 1): S78.
20. Recipe A, Parigi A, Berilaro A, Taluti R, Massacesi L. Safety profile of azathioprine and interferon beta-1a association, in relapsing-remitting multiple sclerosis. ECTRIMS 19th Congress. Mult Scler 2003; 9 (Suppl 1): S29.
21. Weiner HL, Cohan JA. Treatment of multiple sclerosis with cyclophosphomide: critical review of clinical and immunological effects. Mult Scler 2002; 8: 142-154.
22. Patti F, Reggio E, Fiorillo T, Nicoletti A, Palermo F, Reggio A. Rapidly transitional multiple sclerosis patients treated with combination of cyclophosphamide and interferon beta: follow-up 36 months after discontinuation of therapy. AAN 55th Annual Meeting. Neurology 2003; 60 (Suppl 1): A148.
23. Smith DR, Weinstock-Guttmann B, Cohen JA, Guttmann C, Olek MJ, Stuart WH et al. Design of randomized, blinded, MRI trial of pulse cyclophosphamide rescue therapy in B-IFN resistant active MS. AAN 53rd Annual Meeting. Neurology 2001; 56 (Suppl 3): A356.
24. Kaufman M, Norton J, Sonnenfeld G. Safety and tolerability of the combination of interferon beta-1a and oral cyclophosphamide for patients with multiple sclerosis. AAN 53rd Annual Meeting. Neurology 2001; 56 (Suppl 3): A354.
25. Totaro R, Russo T, Marini C, Carolei A. Association of interferon beta and cyclophosphamide in patients with multiple sclerosis. ECTRIMS 19th Congress. Multiple Sclerosis 2003; 9 (Suppl 1): S78.
26. Goodkin DE, Rudick RA, Vanderbrug Medendorp S, Doughtry MM. Low-dose oral methotrexate in chronic progressive multiple sclerosis. Analyses of serial MRIs. Neurology 1996; 47: 1153-1157.
27. Calabresi PA, Wilterdink JL, Rogg JM, Mills P, Webb A, Whartenby KA. An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS. Neurology 2002; 58: 314-317.
28. Rowe VD, Wang D, John HA, Dressman LA, Rowe ES, Moreng GR. Rescue therapy with high dose intravenous methotrexate in MS patients worsening despite Avonex therapy. AAN 55th Annual Meeting. Neurology 2003; 60 (Suppl 1): A149.
29. Cohen J, Antel J, Calabresi P, Fisher E, Goodkin D, Goodman A et al. for the ACT Investigators. Rationale and design of the Avonex combination trial. ECTRIMS 19th Congress. Mult Scler 2003; 9 (Suppl 1): S139-S140.
30. Tran GT, Carter N, Hodgkinson SJ. Mycophenolate mofetil treatment accelerates recovery from experimental allergic encephalomyelitis. Int Immunopharmacol 2001; 1: 1709-1723.
31. Vermersch P, Waucquier N, Bourteel H, Stojkovic T, Fernby D, Michelin E et al. on behalf of the G-SEP. Combination of interferon beta-1a (Avonex) and mycophenolate mofetil (Cellcept) phase II trial in relapsing-remitting multiple sclerosis. ECTRIMS 19th Congress. Mult Scler 2003; 9 (Suppl 1): S18.
32. Lemster B, Huang LL, Irish W, Woo J, Carroll PB, Abu-Elmagd K et al. Influence of FK 506 (tacrolimus) on circulating CD4+ T cells expressing CD25 and CD45RA antigens in 19 patients with chronic progressive multiple sclerosis participating in an open label drug safety trial. Autoimmunity 1995; 19: 89-98.
33. Jacques F. Safety and tolerability of interferon beta-1b in combination with tacrolimus in the treatment of relapsing-remitting multiple sclerosis and SPMS. ECTRIMS 19th Congress. Mult Scler 2003; 9 (Suppl 1): S95-S96.
34. Hecht M, Muller M, Lohmann-Matthes ML, Emmendorffer A. In vitro and in vivo effects of pentoxifylline on macrophages and lymphocytes derived from autoimmune MRL-lpr/lpr mice. J Leukoc Biol 1995; 57: 242-249.
35. Stosic-Grujicic S, Maksimovic D, Badovinac V, Samardzic T, Trajkovic V, Lukic M et al. Antidiabetogenic effect of pentoxifylline is associated with systemic and target tissue modulation of cytokines and nitric oxide production. J Autoimmun 2001; 16: 47-58.
36. Weber F, Polak T, Gunther A, Kubuschok B, Janovskaja J, Bitsch A et al. Synergistic immunomodulatory effects of interferon-beta 1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis. Ann Neurol 1998; 44: 27-34.
37. Qu ZX, Dayal A, Jensen MA, Arnason BG. All-trans retinoic acid potentials the ability of interferon beta-1b to augment suppressor cell function in multiple sclerosis. Arch Neurol 1998; 55: 315-321.
38. Kubera M, Simbirtsev A, Mathison R, Maes M. Effects of repeated fluoxetine and citalopram administration on cytokine release in C57BL/6 mice. Psychiatry Res 2000; 96: 255-266.
39. Makhlouf K, Weiner HL. Increased percentage of IL-12+ monocytes in the blood correlates with the presence of active MRI lesions in MS. J Neuroimmunol 2001; 119: 145-149.
40. Alterman S. Double-blind study comparing the effectiveness of Avonex and Prozac versus Avonex and placebo. US National Multiple Sclerosis Society. Available at: www.nationalmssociety.org/Trials-NewYork.asp (last accessed 3 November 2003).
41. Bielekova B, Reichert-Scrivner S, Wuerfel J, Ohayon J, McCartin J, Richert N et al. Combination therapy of MS patients with incomplete response to interferon-beta with humanized antibody against the interleukin-2 receptor alpha chain. ACTRIMS 7th Annual Meeting, ECTRIMS 18th Congress. Mult Scler 2002; 8 (Suppl 1): S4.
42. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA et al. A controlled trial of notalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15-23.
43. Vollmer T, Phillips JT, Goodman A, Agius M, Shah J, Gross J. Safety, pharmacokinetic (PK), and pharmacodynamic (PD) drug interaction study of antegren and interferon beta-1A (IFNβ-1a, Avonex) in patients with relapsing remitting multiple sclerosis. ECTRIMS 16th Congress. Rev Neurol 2000; 156 (Suppl 3): S127.
44. Rudick R, Calabresi P, Confavreux C, Galetta S, Hartung HP, Radu EW et al. Baseline patient characteristics of the SENTINEL study: a study designed to determine the efficacy and safety of natalizumab (Antegren) in combination with interferon beta-1a (Avonex) for the treatment of relapsing-remitting multiple sclerosis (RRMS). ECTRIMS 19th Congress. Mult Scler 2003; 9 (Suppl 1): S141-142.
45. Rio J, Bonaventura I, Arroyo R, Genis D, Sureda B, Ara JR et al. Steroids, ibuprofen and acetaminophen for flu-like symptoms induced by intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis. ECTRIMS 19th Congress. Mult Scler 2003; 9 (Suppl 1): S26.
46. Salama HH, Kolar OJ, Zang YC, Zhang J. Effects of combination therapy of beta-interferon 1a and prednisone on serum immunologic markers in patients with multiple sclerosis. Mult Scler 2003; 9: 28-31.
47. Pozzilli C, Antonini G, Bagnato F, Mainero C, Tomassini V, Onesti E et al. Monthly corticosteroids decrease neutralizing antibodies to IFN beta 1b: a randomized trial in multiple sclerosis. J Neurol 2002; 249: 50-56.
48. Gonsette RE, D'hooghe BD, De Deyn P, Decoo D, Dupuis M, Guillaume D et al. Association of beta-interferon and inosine in relapsing-remitting multiple sclerosis. ECTRIMS 19th Congress. Mult Scler 2003; 9 (Suppl 1): S141.
49. Kuhmonen J, Jolkkonen J, Haapalinna A, Sivenius J. The neuroprotective effects of (-) deprenyl in the gerbil hippocampus following transient global ischemia. J Neural Transm 2000; 107: 779-786.
50. Caen C, Din M, Khan O. Open-label safety study of combining selegeline with glatiramer acetate in patients with multiple sclerosis: neuroprotection by combining immunomodulation and genetic modulation. ECTRIMS 19th Congress. Mult Scler 2003; 9 (Suppl 1): S141.
51. Dubois B, D'hooghe MB, De Lepeleire K, Ketelaer P, Opdenakker G, Carton H. Toxicity in a double-blind, placebo-controlled pilot trial with D-penicillamine and metacycline in secondary progressive multiple sclerosis. Mult Scler 1998; 4: 74-78.
52. Saida K, Zhigang Z, Ozawa K, Konishi T, Saida T. Long-term open-trial of mizoribine with prednisolone in 24 patients with multiple sclerosis: safety, clinical and magnetic resonance imaging outcome. Intern Med 1999; 38: 636-642.
53. Kalanie H, Tabatabai SS. Combined immunoglobulin and azathioprine in multiple sclerosis. Eur Neurol 1998; 39: 178-181.
54. Visser LH, Beekman R, Tijssen CC, Uitdehaag BM, Movig C, Lenderink B. A randomized, double-blind, placebo-controlled study of intravenous immune globulins (IVIG) in combination with intravenous methylprednisolone (MP) in the treatment of relapses in patients with multiple sclerosis (MS). ACTRIMS 7th Annual Meeting, ECTRIMS 18th Congress. Mult Scler 2002; 8 (Suppl 1): S118.
55. Soelberg Sorensen P, Haas J, Sellebjerg F, Olsson T, Ravnborg, TARIMS Study Group. Intravenous immunoglobulins as add-on treatment to methylprednisolone for acute relapses in multiple sclerosis. ECTRIMS 19th Congress. Mult Scler 2003; 9 (Suppl 1): S26.
56. Caon C, Zwartau-Hind M, Din M, Tselis A, Lisak R, Khan O. Combination therapy with glatiramer acetate (GA) and intravenous methylprednisolone (IVMP) in relapsing-remitting multiple sclerosis (RRMS) patients at high risk of secondary progression. ECTRIMS 17th Congress. Mult Scler 2001; 7 (Suppl 1): S58.
57. Jacob A, McCoy K, Boggild MD. Inducing and maintaining remission in aggressive relapsing-remitting multiple sclerosis: experience of sequential treatment with mitoxantrone and glatiramer acetate. ECTRIMS 19th Congress. Mult Scler 2003; 9 (Suppl 1): S18.
58. Cook S. Double-blind, placebo-controlled study to determine safety and effectiveness of copaxone and albuterol association. US National Multiple Sclerosis Society. Available at: http://www.msnewengland.org/combined.html (last accessed 4 November 2003).
59. Then Bergh F, Kumpfel T, Grasser A, Rupprecht R, Holsboer F, Trenkwalder C. Combined treatment with corticosteroids and moclobemide favors normalization of hypothalamo-pituitary-adrenal axis dysregulation in relapsing-remitting multiple sclerosis: a randomized, double blind trial. J Clin Endocrinol Metab 2001; 86: 1610-1615.
60. Puri BK, Bydder GM, Chaudhuri R, Al Saffar BYS, Curati WL, White SJ et al. MRI changes in multiple sclerosis following treatment with lofepramine and L-phenylalanine. Neuroreport 2001; 12: 1821-1824.
61. Weinstock-Guttman B, Baier M, Feichter J, Gallagher E, Vekatraman J, Meksawan K et al. A randomized study of low fat diet with ω-3 fatty acid supplementation in patients with relapsing-remitting multiple sclerosis. AAN 55th Annual Meeting. Neurology 2003; 60 (Suppl 1) A151.
62. Paty DW, Li DKB. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and IFNB Multiple Sclerosis Study Group. Neurology 1993; 43: 662-667.
63. Palace J, Rothwell P. New treatments and azathioprine in multiple sclerosis. Lancet 1997; 350: 261.
64. Confavreux C, Saddier P, Grimaud J, Moreau T, Adeleine P. Risk of cancer from azathioprine therapy in multiple sclerosis: A case-control study. Neurology 1996; 46: 1607-1612.
65. Le Page E, Leray E, Debouverie M, Pelletier J, Malikova I, Clanet M et al. Induction treatment with mitoxantrone in worsening relapsing remitting multiple sclerosis: a 'rescue therapy' for sub-optimal responders to interferon beta? A pilot study. AAN 55th Annual Meeting. Neurology 2003; 60 (Suppl 1): A149.
66. Tellez N, Pericot I, Rovira A, Galan I, Arevalo MJ, Porcel J et al. Mitoxantrone in multiple sclerosis patients non-responders to beta interferon. ECTRIMS 19th Congress. Mult Scler 2003; 9 (Suppl 1): S79.
67. Jacques F, Carignan MJ, Dumais N, Halle D. Retrospective study of multiple sclerosis patients who received mitoxantrone in combination with interferon beta and/or IV solumedrol. ECTRIMS 19th Congress. Mult Scler 2003; 9 (Suppl 1): S121.
68. Starzl TE, Murase N, Abu-Elmagd K, Gray EA, Shapiro R, Eghtesad B et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003; 361: 1502-1510.